BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
Regulatory & Policy · 25 Jul 2026
FDA Advisory Panel Votes to Recommend BPC-157, KPV, TB-500 and MOTS-c for Compounding — Defying Its Own Scientists
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on 23 July 2026 to recommend four peptides — BPC-157, KPV, TB-500, and MOTS-c — for inclusion on the 503A Bulk Drug Substances List, against the agency's own staff recommendations. Day 2 votes on Emideltide, Semax, and Epitalon conclude today. The panel's recommendations are non-binding, and formal rulemaking could take twelve months or more.
Read briefing →
Research Pipeline
MOTS-c: The Mitochondrial Peptide at the Centre of the July 2026 PCAC Review
MOTS-c, a 16-amino-acid peptide encoded by mitochondrial DNA, is one of four compounds scheduled for discussion on Day 1 of the FDA's Pharmacy Compounding Advisory Committee meeting on 23 July 2026. With the deadline for oral testimony registration falling on 30 June, UK research-procurement professionals have a narrow window to understand what the evidence base actually shows — and what a favourable committee recommendation would and would not mean.
04 Jul 2026
Reputational Risks
Retatrutide's Illicit Market: What the Surge in Unlicensed "Research Peptide" Sales Means for UK Labs
An investigative report from CBS News published on 8 June 2026, combined with MHRA enforcement raids in the UK and a 265% rise in US poison centre exposures, has brought renewed scrutiny to the grey and black markets for retatrutide. For legitimate research procurement teams, the episode illustrates exactly why the "research-use only" label is under intensifying regulatory pressure on both sides of the Atlantic.
04 Jul 2026
Research Pipeline
Retatrutide: What the TRIUMPH-1 Phase 3 Data and NDA Timeline Mean for Peptide Research Procurement
Eli Lilly's triple-agonist retatrutide posted a 28.3% average weight loss at 80 weeks in the Phase 3 TRIUMPH-1 trial — the largest efficacy signal ever recorded in a randomised obesity study. With an NDA submission targeted for Q4 2026 and a grey market already active, procurement teams need to understand what the compound is, where it stands legally, and how to source it responsibly for legitimate research.
25 Jun 2026
Reputational Risks
MHRA Turns Its Attention to UK Peptide Clinics: What the April 2026 Investigation Means for Legitimate Research Labs
The MHRA has opened investigations into UK clinics making therapeutic claims about unregulated peptide products, following a Guardian exposé and an earlier Criminal Enforcement Unit raid in Lincolnshire. For research-procurement professionals, the enforcement shift clarifies where regulatory tolerance ends — and why robust research-use-only labelling and sourcing discipline matter more than ever.
02 Jun 2026
Pharma & GLP-1
Regeneron's $2.3 Billion Bet on Helicon Peptides: What the Parabilis Deal Signals for the Peptide Research Landscape
Regeneron Pharmaceuticals announced a research collaboration with Parabilis Medicines on 18 May 2026, valued at up to $2.32 billion, centred on Helicons — stabilised, cell-penetrant alpha-helical peptides designed to reach intracellular targets that have long resisted conventional drug design. The deal crystallises a strategic shift in how institutional capital now views structurally engineered peptides, with implications extending well beyond oncology.
01 Jun 2026
Pharma & GLP-1
Orforglipron's ATTAIN-MAINTAIN Data Clarifies the Sequential GLP-1 Strategy — and Redraws Research Priorities for Peptide Labs
The ATTAIN-MAINTAIN trial, published in Nature Medicine on 12 May 2026, shows that switching from injectable GLP-1s to oral orforglipron (Foundayo) preserved roughly 75–80% of prior weight loss over 52 weeks. For research-procurement teams, the data crystallises a new sequential treatment paradigm — and raises pointed questions about which peptide and non-peptide reference compounds will be in demand next.
01 Jun 2026
Research Pipeline
Semax: The Russian-Approved Neuropeptide Now at the Centre of the FDA's July 2026 Compounding Review
Semax, a synthetic ACTH-derived heptapeptide approved in Russia for stroke recovery and cognitive impairment, was removed from the FDA's Category 2 restricted compounding list in April 2026 and is now scheduled for formal PCAC review on 24 July 2026. For UK research-procurement teams, its regulatory trajectory — and the evidentiary questions the advisory panel must resolve — make it one of the more consequential peptides to monitor this summer.
01 Jun 2026
Regulatory & Policy
The PCAC July 2026 Hearing: What the Four Day-One Peptides — BPC-157, TB-500, KPV, and MOTS-c — Need to Prove Before the Review
On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee will evaluate BPC-157, TB-500, KPV, and MOTS-c for potential inclusion on the Section 503A Bulk Drug Substances List. With the oral-testimony registration deadline on 30 June and the cut-off for comments reaching the committee on 9 July, procurement teams have weeks — not months — to understand what is at stake.
01 Jun 2026
Pharma & GLP-1
Retatrutide's TRIUMPH-1 Phase 3 Data: 28.3% Weight Loss, a Pending NDA, and What It Means for Research Labs
Eli Lilly's triple agonist retatrutide delivered up to 28.3% average body-weight reduction at 80 weeks in the Phase 3 TRIUMPH-1 trial, with a 30.3% result at 104 weeks in a high-BMI sub-group. The data, released 21 May 2026, sets a new efficacy benchmark in the GLP-1 class — and is already intensifying procurement interest in research-grade retatrutide, despite the compound remaining strictly investigational and not compoundable under any current legal pathway.
30 May 2026
Industry & Community
The Macrocyclic Peptide Investment Wave: What Three Major 2026 Deals Signal for the Research Landscape
A cluster of substantial deals in early 2026 — including Novartis's $100 million upfront commitment to Unnatural Products, Syneron Bio's $150 million Series B, and AstraZeneca's ongoing $3.4 billion biobucks arrangement — marks macrocyclic peptides as the modality attracting the most concentrated institutional attention in the peptide space. For research-procurement teams, understanding what distinguishes macrocycles from conventional linear peptides, and why big pharma is now paying platform…
30 May 2026
Research Pipeline
Oral Peptide Therapeutics Reach an Inflection Point: ICOTYDE's Approval, Pinnacle's $89M Raise, and What the Delivery Revolution Means for Research Labs
The FDA approval of icotrokinra (ICOTYDE) as the first targeted oral peptide to block the IL-23 receptor marks a structural shift in peptide drug delivery. Combined with a wave of investment in oral-peptide platforms and an upcoming PCAC advisory meeting, the field is entering a period of rapid technical and regulatory change that procurement teams need to understand.
29 May 2026